Fomivirsen

Drug Profile

Fomivirsen

Alternative Names: Fomivirsen sodium; ISIS 2922; Vitravene

Latest Information Update: 16 Jan 2016

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Isis Pharmaceuticals; Pacira Pharmaceuticals
  • Class Antisense oligonucleotides; Antivirals; Thionucleotides
  • Mechanism of Action RNA binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Cytomegalovirus infections

Most Recent Events

  • 11 Jan 2016 Ionis Pharmaceuticals completes a phase I/II trial in Cytomegalovirus infections in USA (Ophthalmic) before June 2005 (NCT00002187)
  • 18 Nov 2005 Fomivirsen has received Orphan Drug Status for CMV-induced retinitis in AIDS patients in Australia
  • 30 Jul 2002 Withdrawn for Cytomegalovirus infections in European Union (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top